FDA authorizes first AI tech for visualizing coronary inflammation in CT scans

The US FDA has granted de novo market clearance to Caristo Diagnostics' CaRi-Heart technology. This is the first AI-powered tool that can directly visualize and quantify coronary inflammation from standard CT scans, enabling a more precise assessment of a patient's future heart attack risk.

This Wire brief sits within Fusion42's coverage of Diagnostics. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.